1)Kawamori R, et al:Voglibose for prevention of type 2 diabetes mellitus:a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 373(9675):1607-1614, 2009
2)Scheen AJ:Voglibose for prevention of type 2 diabetes mellitus. Lancet 373(9675):1579-1580, 2009
3)Diabetes Prevention Program Research Group:Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346(6):393-403, 2002
4)Diabetes Prevention Program Research Group:Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up:the Diabetes Prevention Program Outcomes Study. Lancet Diab Endoc 3(11):866-875, 2015
5)Chiasson JL, et al:Acarbose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randomized trial. Lancet 359(9323):2072-2077, 2002
6)Chiasson JL, et al:Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance:the STOP-NIDDM trial. JAMA 290(4):486-494, 2003
7)DeFronzo RA, et al:Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 364(12):1104-1115, 2011
8)DeFronzo RA, et al:Prevention of diabetes with pioglitazone in ACT NOW:physiologic correlates. Diabetes 62(11):3920-3926, 2013
9)Tripathy D, et al:Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW. Diabetes Care 37(6):1706-1711, 2014
10)河盛隆造:糖のながれにおける肝・糖取り込み率制御因子の解明.糖尿病49(10):771-773, 2006